Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment

[1]  J. Weinstein,et al.  Catalytic Role of the Substrate Defines Specificity of Therapeutic l-Asparaginase. , 2015, Journal of molecular biology.

[2]  R. Kuiper,et al.  A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics. , 2014, Blood.

[3]  Y. Kohno,et al.  Expression of CD203c on basophils as a marker of immunoglobulin E-mediated l-asparaginase allergy , 2014, Leukemia & lymphoma.

[4]  M. Leach,et al.  Immunogenicity/Hypersensitivity of Biologics , 2014, Toxicologic pathology.

[5]  W. Tissing,et al.  A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. , 2013, Blood.

[6]  M. Relling,et al.  Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Relling,et al.  Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia , 2011, Leukemia.

[8]  M. Relling,et al.  Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. , 2012, Blood.

[9]  J. Gerss,et al.  Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. , 2011, Blood.

[10]  C. M. Cadwell,et al.  Transfusion of minor histocompatibility antigen-mismatched platelets induces rejection of bone marrow transplants in mice. , 2009, The Journal of clinical investigation.

[11]  Marc N. Offman,et al.  A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. , 2009, The Journal of clinical investigation.

[12]  B. Sekerel,et al.  Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia. , 2009, The Journal of allergy and clinical immunology.

[13]  W. Młynarski,et al.  The cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparations , 2009, Clinical and Experimental Medicine.

[14]  M. Relling,et al.  Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Młynarski,et al.  The anti-asparagines antibodies correlate with l-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia , 2007, Leukemia & lymphoma.

[16]  W. Andrzejewski,et al.  Development of anti‐asparaginase antibodies in childhood acute lymphoblastic leukemia , 2004, Pediatric blood & cancer.

[17]  H. Sather,et al.  Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children's Cancer Group Study CCG-1961 , 2004, Journal of pediatric hematology/oncology.

[18]  S. Suciu,et al.  Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. , 2002, Blood.

[19]  J. Neglia,et al.  A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. , 2002, Blood.

[20]  R. Pieters,et al.  Asparagine synthetase activity in paediatric acute leukaemias: AML‐M5 subtype shows lowest activity , 2000, British journal of haematology.

[21]  M. Relling,et al.  Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  N. Cheung,et al.  Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. , 1986, The American journal of pediatric hematology/oncology.

[23]  V. Wahn,et al.  Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children--evidence of a complement-mediated mechanism. , 1985, Pediatric research.

[24]  J. Palmblad,et al.  Hypersensitive reactions and antibody formation during L‐asparaginase treatment of children and adults with acute leukemia , 1976, Cancer.

[25]  J. Broome.  STUDIES ON THE MECHANISM OF TUMOR INHIBITION BY L-ASPARAGINASE , 1968, The Journal of experimental medicine.